Author

Zhen Fang

Shanghai Jiao Tong UniversityPrimary ORCID profile (0000-0001-9708-3823 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Zhen FangiD1 paper · Shanghai Jiao Tong University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Ao Gu· 1 shared Fabao Chen· 1 shared Fan XuiD· 1 shared Longxing CaoiD· 1 shared Maolan Li· 1 shared Ruobing Yu· 1 shared Weikang Yan· 1 shared Yali Liu· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ao Gu

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Nab-paclitaxel fused with the de novo designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacy

Yuanying Qian, Weikang Yan, Fan Xu, Yali Liu, Fabao Chen, Yue Lu, Zihan Zhang, Ao Gu, Ruobing Yu, Zhen Fang, Yang Yu, Maolan Li, Longxing Cao, Yingbin Liu, Yongning He

This paper modifies Nab-paclitaxel with receptor binders to improve tumor targeting and reduce toxicity, showing enhanced efficacy in cancer cells and xenograft models.

Journal of Controlled Release · Sep 15, 2026Peer-reviewedCancer Biology